Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Superior Efficacy of Helicase-Primase Inhibitor BAY 57–1293 for Herpes Infection and Latency in the Guinea Pig Model of Human Genital Herpes Disease

1 Feb 2007

Abstract excerpt

The efficacy of BAY 57-1293, a novel non-nucleosidic inhibitor of herpes simplex virus 1 and 2 (HSV-1 and HSV-2), bovine herpesvirus and pseudorabies virus, was studied in the guinea pig model of genital herpes in comparison with the licensed drug valaciclovir (Valtrex). Early therapy with BAY 57-1293 almost completely suppressed the symptoms of acute HSV-2 infection, and reduced virus shedding and viral load in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Herpesvirus Infections and Treatments
Share to Vector-Borne Animal Diseases
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17354650
DOI: 10.1177/095632020701800104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Superior Efficacy of Helicase-Primase Inhibitor BAY 57–1293 for Herpes Infection and Latency in the Guinea Pig Model of Human Genital Herpes DiseasePMID 17354650Read ↗

AAV-delivered gene editing for latent genital or orofacial herpes simplex virus infection reduces ganglionic viral load and minimizes subsequent viral shedding in miceSemantic proximity Read ↗

Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivoSemantic proximity Read ↗

Helicase–Primase Inhibitor Pritelivir for HSV-2 InfectionSemantic proximity Read ↗

Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.Semantic proximity Read ↗

Clinical management of herpes simplex virus infections: past, present, and futureSemantic proximity Read ↗

LAVR-289, an Acyclo-Nucleoside Phosphonate, Has Broad-Spectrum Activity against HerpesvirusesSemantic proximity Read ↗

Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses.Semantic proximity Read ↗

Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.Semantic proximity Read ↗

Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of actionSemantic proximity Read ↗

Helicase‐Primase as a Target of New Therapies for Herpes Simplex Virus InfectionsSemantic proximity Read ↗

Detection of HSV-1 variants highly resistant to the helicase–primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1Semantic proximity Read ↗

The DNA helicase–primase complex as a target for herpes viral infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.